Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
- 1 December 2004
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 61 (6), 704-710
- https://doi.org/10.1111/j.1365-2265.2004.02153.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2003
- Thyroid StunningThyroid®, 2003
- The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131 IEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Relationship Between Tumor Burden and Serum Thyroglobulin Level in Patients with Papillary and Follicular Thyroid CarcinomaThyroid®, 2002
- Are Posttherapy Radioiodine Scans Informative and Do They Influence Subsequent Therapy of Patients with Differentiated Thyroid Cancer?Thyroid®, 2000
- Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphyNuclear Medicine Communications, 2000
- Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scansNuclear Medicine Communications, 1996
- Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomyNuclear Medicine Communications, 1988
- Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancerCancer, 1988